• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Overview Of Value Stocks In The Healthcare Sector

    11/27/23 9:43:28 AM ET
    $FWBI
    $KPRX
    $OGN
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FWBI alert in real time by email

    Understanding Value Stocks

    A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

    The following stocks are considered to be notable value stocks in the healthcare sector:

    1. First Wave BioPharma (NASDAQ:FWBI) - P/E: 0.0
    2. Kiora Pharmaceuticals (NASDAQ:KPRX) - P/E: 0.71
    3. TherapeuticsMD (NASDAQ:TXMD) - P/E: 0.61
    4. Voyager Therapeutics (NASDAQ:VYGR) - P/E: 5.89
    5. Organon (NYSE:OGN) - P/E: 4.98

    First Wave BioPharma has reported Q2 earnings per share at $-1.89, which has decreased by 3.85% compared to Q1, which was -1.82. Kiora Pharmaceuticals has reported Q3 earnings per share at $-0.89, which has decreased by 12.66% compared to Q2, which was -0.79. TherapeuticsMD saw an increase in earnings per share from -0.24 in Q2 to $-0.13 now. Voyager Therapeutics saw a decrease in earnings per share from -0.51 in Q2 to $-0.59 now. This quarter, Organon experienced a decrease in earnings per share, which was $1.31 in Q2 and is now $0.87. Its most recent dividend yield is at 7.65%, which has increased by 2.51% from 5.14% in the previous quarter.

    These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.

    Get the next $FWBI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FWBI
    $KPRX
    $OGN
    $TXMD

    CompanyDatePrice TargetRatingAnalyst
    Organon & Co.
    $OGN
    12/9/2025$7.50Underweight
    Barclays
    Organon & Co.
    $OGN
    10/27/2025$5.00Overweight → Underweight
    Piper Sandler
    Organon & Co.
    $OGN
    5/2/2025Outperform → In-line
    Evercore ISI
    Voyager Therapeutics Inc.
    $VYGR
    1/10/2025Overweight
    Cantor Fitzgerald
    Voyager Therapeutics Inc.
    $VYGR
    12/2/2024$12.00Buy
    Citigroup
    Voyager Therapeutics Inc.
    $VYGR
    11/29/2024$7.00 → $11.00Outperform
    Wedbush
    Voyager Therapeutics Inc.
    $VYGR
    10/16/2024$15.00Outperform
    Leerink Partners
    Organon & Co.
    $OGN
    9/6/2024$18.00 → $20.00Neutral → Underweight
    JP Morgan
    More analyst ratings

    $FWBI
    $KPRX
    $OGN
    $TXMD
    SEC Filings

    View All

    Voyager Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)

    3/9/26 4:04:13 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Voyager Therapeutics Inc.

    10-K - Voyager Therapeutics, Inc. (0001640266) (Filer)

    3/9/26 4:02:12 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Voyager Therapeutics Inc.

    144 - Voyager Therapeutics, Inc. (0001640266) (Subject)

    2/24/26 5:10:03 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FWBI
    $KPRX
    $OGN
    $TXMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy

    12/29/21 7:23:57 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for IMVEXXY issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug IMVEXXY (SUPPL-2) with active ingredient ESTRADIOL has changed to 'Approval' on 11/16/2021. Application Category: NDA, Application Number: 208564, Application Classification: Labeling

    11/17/21 4:38:32 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-3) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 06/22/2021. Application Category: NDA, Application Number: 210132, Application Classification: Labeling

    6/24/21 5:13:50 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FWBI
    $KPRX
    $OGN
    $TXMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Organon with a new price target

    Barclays initiated coverage of Organon with a rating of Underweight and set a new price target of $7.50

    12/9/25 8:51:54 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Organon from Overweight to Underweight and set a new price target of $5.00

    10/27/25 11:23:41 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon downgraded by Evercore ISI

    Evercore ISI downgraded Organon from Outperform to In-line

    5/2/25 8:13:50 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FWBI
    $KPRX
    $OGN
    $TXMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kiora Pharmaceuticals Inc.

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/10/26 4:36:21 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kiora Pharmaceuticals Inc.

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/10/26 4:37:12 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Strem Brian M. was granted 16,733 shares, increasing direct ownership by 36% to 62,598 units (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/10/26 4:36:52 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FWBI
    $KPRX
    $OGN
    $TXMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -  - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile - - Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 - LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2025 financial and operating r

    3/9/26 4:01:00 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

    Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, Pennsylvania, on February 27, 2026. The findings show that VTAMA cream prov

    2/27/26 8:00:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device

    MIUDELLA® is a strategic addition to Organon's portfolio, strengthening its long‑term commitment to advancing women's health Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA's alternate supply chain entities and certain other conditions.

    2/23/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FWBI
    $KPRX
    $OGN
    $TXMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thompson Tommy G bought $14,031 worth of shares (8,400 units at $1.67), increasing direct ownership by 57% to 23,179 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    12/29/25 4:23:31 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chair Cox Carrie Smith bought $501,755 worth of shares (65,400 units at $7.67) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    11/13/25 4:05:10 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cox Carrie Smith bought $100,591 worth of shares (12,469 units at $8.07) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/15/25 4:09:09 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FWBI
    $KPRX
    $OGN
    $TXMD
    Leadership Updates

    Live Leadership Updates

    View All

    Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

    Organon (NYSE:OGN) ("Organon" or "the company") today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Morrissey in his new role. Director Robert Essner will assume the role of Lead Independent Director. These appointments follow the resignation of Kevin Ali as Chief Executive Officer and member of the Board in connection with the Audit Committee investigation described below. Mr. Ali has agreed that he will not be entitled to severance o

    10/27/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Appoints Ramona A. Sequeira to the Company's Board of Directors

    Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac

    4/15/25 5:00:00 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO

    Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic Ovary Syndrome (PCOS), today announced that Colby Holtshouse has joined the Company as President and CEO. Colby brings a wealth of senior leadership and women's health expertise to the organization, having held executive positions with Organon (NYSE:OGN), Alydia Health, and Pel

    3/10/25 12:01:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FWBI
    $KPRX
    $OGN
    $TXMD
    Financials

    Live finance-specific insights

    View All

    Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

    Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency Full year 2025 diluted earnings per share of $0.72 and non-GAAP Adjusted diluted earnings per share of $3.66 Full year 2025 Adjusted EBITDA of $1.91 billion inclusive of $6 million of IPR&D, representing a 30.7% Adjusted EBITDA margin The company expects to deliver approximately $6.2 billion of revenue and approximately $1.9 billion of Adjusted EBITDA for the full year 2026, both measures in-line with full year 2025 performance. Organon (NYSE:OGN) today announced its results for the fourth quarter and full year ended December 31, 2025. "In 2025 we took action that demonstrate

    2/12/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

    Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its fourth quarter and full year 2025 financial results on February 12, 2026, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the fourth quarter of 2025. Organon's fourth quarter and full year 2025 results have not been finalized and are subject to the company's quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing Fourth Quarter and Full Year 2025 F

    1/29/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Reports Results for the Third Quarter Ended September 30, 2025

    Third quarter 2025 revenue of $1.602 billion, up 1% as-reported and down 1% excluding the impact of foreign currency Third quarter 2025 diluted earnings per share of $0.61 and non-GAAP Adjusted diluted earnings per share of $1.01 Third quarter 2025 net income of $160 million and Adjusted EBITDA (non-GAAP) of $518 million, representing an Adjusted EBITDA margin of 32.3% Revenue guidance range for full year 2025 lowered to $6.200 billion to $6.250 billion; Adjusted EBITDA margin guidance lowered to ~31.0% Organon (NYSE:OGN) today announced its results for the third quarter ended September 30, 2025. "I am humbled to be working alongside our talented team during this pivotal time

    11/10/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FWBI
    $KPRX
    $OGN
    $TXMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

    SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

    11/14/24 7:17:24 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

    SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    11/14/24 6:13:11 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

    SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    11/14/24 5:12:26 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care